Comment on “Fecal occult blood versus DNA testing: indirect comparison in a colorectal cancer screening population”
David A Ahlquist
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
Challenges to medical innovation are welcome and essential elements in the dialectic toward practice optimization but must be based on scientifically sound criticism. A multi-target stool DNA test (MT-sDNA) has emerged as a new approach to colorectal cancer (CRC) screening, and in the US, it is approved by federal regulatory bodies, endorsed in societal screening guidelines, and covered by government and private insurers. In their recent paper,1 Brenner and Chen concluded that CRC screening sensitivity by fecal immunochemical test (FIT) for occult blood is equal to or better than that of MT-sDNA when tests are compared at matched specificity. However, concerns can be raised regarding their methodology and data.
Hermann Brenner1–3 Hongda Chen1,4
1Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 2Division of Preventive Oncology, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), 3German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany; 4Program Office for Cancer Screening in Urban China, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing, People’s Republic of China
We appreciate Dr. Ahlquist’s interest in our article1 that challenges his previously disseminated claim that the multitarget stool DNA test (MSDT) represents “the new high bar benchmark for noninvasive CRC screening”.2
View the original paper by Brenner and Chen.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]